Olaparib tablet dosing

DRUG4 trials

Sponsors

AstraZeneca

Conditions

Solid Tumours

Phase 1

Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment

CompletedNCT01894243

AstraZenecaSolid Tumours

Start: 2014-03-13End: 2017-03-30Updated: 2019-09-13

Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal or Impaired Kidney Function

CompletedNCT01894256

AstraZenecaSolid Tumours

Start: 2013-11-30End: 2016-02-29Updated: 2016-10-13

To Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of Olaparib, and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation to Patients With Advanced Solid Tumours

CompletedNCT01900028

AstraZenecaSolid Tumours

Start: 2013-10-31End: 2016-09-30Updated: 2016-10-17

Study to Assess the Effect of Rifampicin (CYP Inducer) on Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours

CompletedNCT01929603

AstraZenecaSolid Tumours

Start: 2013-12-31End: 2016-11-30Updated: 2017-01-16

Related Papers

Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment.

2019-09-0124 citations

Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies.

2016-10-1049 citations

Olaparib does not cause clinically relevant QT/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies.

2016-08-2312 citations

Effect of itraconazole and rifampin on the pharmacokinetics of olaparib tablet formulation in patients with advanced solid tumours: Phase I open-label studies.

Journal of Clinical Oncology2015-05-201 citations